Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1956 2
1958 1
1961 2
1962 1
1963 1
1964 1
1965 3
1966 1
1968 2
1969 4
1970 3
1971 4
1972 2
1974 1
1975 1
1976 4
1977 8
1978 8
1979 7
1980 10
1981 4
1982 5
1983 3
1984 7
1985 8
1986 7
1987 7
1988 6
1989 3
1990 6
1991 1
1992 1
1993 6
1994 7
1995 11
1996 7
1997 12
1998 11
1999 9
2000 17
2001 16
2002 16
2003 20
2004 14
2005 28
2006 38
2007 31
2008 24
2009 23
2010 24
2011 31
2012 38
2013 32
2014 27
2015 47
2016 37
2017 34
2018 32
2019 34
2020 36
2021 37
2022 46
2023 42
2024 45
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

874 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives.
Lee JM, McNamee CJ, Toloza E, Negrao MV, Lin J, Shum E, Cummings AL, Kris MG, Sepesi B, Bara I, Kurtsikidze N, Schulze K, Ngiam C, Chaft JE. Lee JM, et al. Among authors: schulze k. J Thorac Oncol. 2023 Nov;18(11):1458-1477. doi: 10.1016/j.jtho.2023.07.006. Epub 2023 Jul 13. J Thorac Oncol. 2023. PMID: 37451404 Free PMC article. Review.
Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma.
Calderaro J, Ghaffari Laleh N, Zeng Q, Maille P, Favre L, Pujals A, Klein C, Bazille C, Heij LR, Uguen A, Luedde T, Di Tommaso L, Beaufrère A, Chatain A, Gastineau D, Nguyen CT, Nguyen-Canh H, Thi KN, Gnemmi V, Graham RP, Charlotte F, Wendum D, Vij M, Allende DS, Aucejo F, Diaz A, Rivière B, Herrero A, Evert K, Calvisi DF, Augustin J, Leow WQ, Leung HHW, Boleslawski E, Rela M, François A, Cha AW, Forner A, Reig M, Allaire M, Scatton O, Chatelain D, Boulagnon-Rombi C, Sturm N, Menahem B, Frouin E, Tougeron D, Tournigand C, Kempf E, Kim H, Ningarhari M, Michalak-Provost S, Gopal P, Brustia R, Vibert E, Schulze K, Rüther DF, Weidemann SA, Rhaiem R, Pawlotsky JM, Zhang X, Luciani A, Mulé S, Laurent A, Amaddeo G, Regnault H, De Martin E, Sempoux C, Navale P, Westerhoff M, Lo RC, Bednarsch J, Gouw A, Guettier C, Lequoy M, Harada K, Sripongpun P, Wetwittayaklang P, Loménie N, Tantipisit J, Kaewdech A, Shen J, Paradis V, Caruso S, Kather JN. Calderaro J, et al. Among authors: schulze k. Nat Commun. 2023 Dec 14;14(1):8290. doi: 10.1038/s41467-023-43749-3. Nat Commun. 2023. PMID: 38092727 Free PMC article.
Tissue resident iNKT17 cells facilitate cancer cell extravasation in liver metastasis via interleukin-22.
Giannou AD, Kempski J, Shiri AM, Lücke J, Zhang T, Zhao L, Zazara DE, Cortesi F, Riecken K, Amezcua Vesely MC, Low JS, Xu H, Kaffe E, Garcia-Perez L, Agalioti T, Yamada Y, Jungraithmayr W, Zigmond E, Karstens KF, Steglich B, Wagner J, Konczalla L, Carambia A, Schulze K, von Felden J, May P, Briukhovetska D, Bedke T, Brockmann L, Starzonek S, Lange T, Koch C, Riethdorf S, Pelczar P, Böttcher M, Sabihi M, Huber FJ, Reeh M, Grass JK, Wahib R, Seese H, Stüben BO, Fard-Aghaie M, Duprée A, Scognamiglio P, Plitzko G, Meiners J, Soukou S, Wittek A, Manthey C, Maroulis IC, Arck PC, Perez D, Gao B, Zarogiannis SG, Strowig T, Pasqualini R, Arap W, Gosálvez JS, Kobold S, Prinz I, Guse AH, Tachezy M, Ghadban T, Heumann A, Li J, Melling N, Mann O, Izbicki JR, Pantel K, Schumacher U, Lohse AW, Flavell RA, Gagliani N, Huber S. Giannou AD, et al. Among authors: schulze k. Immunity. 2023 Jan 10;56(1):125-142.e12. doi: 10.1016/j.immuni.2022.12.014. Immunity. 2023. PMID: 36630911 Free PMC article.
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.
D'Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Gaillard VE, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Personeni N, Pressiani T, Sharma R, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato DJ. D'Alessio A, et al. Among authors: schulze k. Hepatology. 2022 Oct;76(4):1000-1012. doi: 10.1002/hep.32468. Epub 2022 Apr 8. Hepatology. 2022. PMID: 35313048 Free PMC article.
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer.
Assaf ZJF, Zou W, Fine AD, Socinski MA, Young A, Lipson D, Freidin JF, Kennedy M, Polisecki E, Nishio M, Fabrizio D, Oxnard GR, Cummings C, Rode A, Reck M, Patil NS, Lee M, Shames DS, Schulze K. Assaf ZJF, et al. Among authors: schulze k. Nat Med. 2023 Apr;29(4):859-868. doi: 10.1038/s41591-023-02226-6. Epub 2023 Mar 16. Nat Med. 2023. PMID: 36928816 Free PMC article.
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
Scheiner B, Pomej K, Kirstein MM, Hucke F, Finkelmeier F, Waidmann O, Himmelsbach V, Schulze K, von Felden J, Fründt TW, Stadler M, Heinzl H, Shmanko K, Spahn S, Radu P, Siebenhüner AR, Mertens JC, Rahbari NN, Kütting F, Waldschmidt DT, Ebert MP, Teufel A, De Dosso S, Pinato DJ, Pressiani T, Meischl T, Balcar L, Müller C, Mandorfer M, Reiberger T, Trauner M, Personeni N, Rimassa L, Bitzer M, Trojan J, Weinmann A, Wege H, Dufour JF, Peck-Radosavljevic M, Vogel A, Pinter M. Scheiner B, et al. Among authors: schulze k. J Hepatol. 2022 Feb;76(2):353-363. doi: 10.1016/j.jhep.2021.09.035. Epub 2021 Oct 12. J Hepatol. 2022. PMID: 34648895 Free article.
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
Fulgenzi CAM, Cheon J, D'Alessio A, Nishida N, Ang C, Marron TU, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Napolitano A, Huang YH, Phen S, Naqash AR, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, Kudo M, Rimassa L, Singal AG, Sharma R, Cortellini A, Gaillard VE, Chon HJ, Pinato DJ. Fulgenzi CAM, et al. Among authors: schulze k. Eur J Cancer. 2022 Nov;175:204-213. doi: 10.1016/j.ejca.2022.08.024. Epub 2022 Sep 20. Eur J Cancer. 2022. PMID: 36148739 Free article.
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.
Fulgenzi CAM, Scheiner B, D'Alessio A, Mehan A, Manfredi GF, Celsa C, Nishida N, Ang C, Marron TU, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Pinter M, Sharma R, Cheon J, Huang YH, Lee PC, Phen S, Gampa A, Pillai A, Napolitano A, Vivaldi C, Salani F, Masi G, Silletta M, Lo Prinzi F, Di Giacomo E, Vincenzi B, Bettinger D, Thimme R, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, Pirisi M, Park JW, Kudo M, Rimassa L, Singal AG, El Tomb P, Ulahannan S, Parisi A, Chon HJ, Hsu WF, Ghittoni G, Cammà C, Stefanini B, Trevisani F, Giannini EG, Cortellini A, Pinato DJ. Fulgenzi CAM, et al. Among authors: schulze k. JAMA Oncol. 2024 Sep 1;10(9):1253-1258. doi: 10.1001/jamaoncol.2024.2166. JAMA Oncol. 2024. PMID: 39023864
Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study.
Dacic S, Travis WD, Giltnane JM, Kos F, Abel J, Hilz S, Fujimoto J, Sholl L, Ritter J, Khalil F, Liu Y, Taylor-Weiner A, Resnick M, Yu H, Hirsch FR, Bunn PA Jr, Carbone DP, Rusch V, Kwiatkowski DJ, Johnson BE, Lee JM, Hennek SR, Wapinski I, Nicholas A, Johnson A, Schulze K, Kris MG, Wistuba II. Dacic S, et al. Among authors: schulze k. J Thorac Oncol. 2024 May;19(5):719-731. doi: 10.1016/j.jtho.2023.12.010. Epub 2023 Dec 7. J Thorac Oncol. 2024. PMID: 38070597
Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial.
Ross HJ, Kozono D, Wang XF, Urbanic JJ, Williams TM, Nelson GD, Carbone DP, Chung D, Robb R, Byun WY, Talabere T, DuFrane C, Bara I, Schulze K, Brockman M, Gao J, Vokes EE, Stinchcombe TE. Ross HJ, et al. Among authors: schulze k. JAMA Oncol. 2024 Sep 1;10(9):1212-1219. doi: 10.1001/jamaoncol.2024.1897. JAMA Oncol. 2024. PMID: 39052256 Clinical Trial.
874 results